Optimal therapeutic combinations for Phase 3 UC trial design- recommendations from a QSP platform model

Model-informed dose priming strategy for T cell engagers: Leveraging early clinical data to mitigate CRS

Bridging Preclinical Data and Human Dose Selection for ADCs: Lessons from Approved Molecules

Quantitative Systems Pharmacology (QSP) Modeling of efficacy and nausea of GLP-1 mono and dual (GLP-1/GIP) receptor agonists (RA) to support weight management and glycemic control in obese patients

Evaluating antibody drug conjugate (ADC) combinations using the platform Quantitative Systems Pharmacology (QSP) model

A Unified Mechanistic Framework for Modeling Short- and Long-Acting siRNAs: Impact of RISC Stability on PD Durability

Model-Informed Strategies for GLP-1 RA Development: Linking PKPD to Weight Loss and Glycemic Control

Predicting Phase3 efficacy of combination therapy in Ulcerative Colitis #IBD

From Xenograft to Clinic: QSP-guided dosing and step-up strategy for CD3×HLA-G T Cell Engagers TCE

Clinical Efficacy and cytokine release syndrome (CRS) risk of CD3 Bispecifics in prostate cancer

Leveraging in vitro data from novel drug candidates to prioritize antibody combinations in autoimmune disease using a QSP model of IBD

QSP model to predict clinical PK/PD of siRNA therapeutics and learnings from model development